Viking Therapeutics (VKTX) is gaining attention as a high-risk, high-reward biotech company focused on obesity treatments. Valued at $4.2 billion, Viking’s lead drug, VK2735, has shown promising results in clinical trials, with encouraging weight loss and tolerability. The company’s financial position remains strong with $715 million in cash and investments.

Viking has advanced VK2735 to Phase 3 trials and is exploring innovative maintenance strategies. With upcoming milestones in 2026, including regulatory discussions and clinical data publication, the company’s potential is significant. Wall Street rates VKTX a consensus “Strong Buy,” with an average target price suggesting a 141% upside potential.

Despite a 9% YTD stock decline, analysts predict substantial upside for Viking, with a high price estimate indicating a 235% increase over the next 12 months. As a key player in the obesity treatment market, Viking’s momentum could lead to significant surprises in 2026 for investors willing to navigate the volatility of a clinical-stage biotech.

Read more at Yahoo Finance: This Small But Mighty Stock Could Surprise Investors in 2026